Cbinsights-技术市场地图报告-医疗器械新产品和服务（英）-2021.9-78页_6mb

Q2'21 Healthcare Report Summary

Core Content

This report outlines the state of healthcare investment and sector trends for Q2'21, highlighting key developments in AI, digital therapeutics, telehealth, omics, medical devices, health IT, and mental health tech. It provides an overview of funding, deal counts, and notable activities across these sectors, emphasizing the ongoing digital transformation and its impact on the healthcare landscape.

Main Points

• Global Healthcare Investment:

  • Funding increased for the seventh consecutive quarter, reaching $34.7B across nearly 1.6K deals.
  • Digital health startups accounted for 40% of both the deals and funding raised, with a total of $14.1B across 628 deals.
  • European investment nearly doubled QoQ to $6.9B, while Asian investment fell for the second quarter in a row but remained elevated compared to pre-Q3'20 levels.

• Deal Stage Trends:

  • Early-stage deal share reached 54%, the highest since Q3'19, driven by a flood of new entrants.
  • M&A activity persisted, with primary care, women's health, and mental health being key acquisition hotspots.

• Top Deals:

  • The top 5 healthcare deals in Q2'21 spanned life sciences, medtech, and digital health.
  • Notable deals included Caris Life Sciences ($830M), CMR Surgical ($600M), Noom ($540M), Exscientia ($525M), and Adagio Therapeutics ($336M).

• SPAC Activity:

  • The SPAC frenzy continued, with 3 companies making public market debuts and 7 others planning to do so.
  • Notable SPAC exits included LumiraDx ($5B), Babylon Health ($4.2B), and 23andMe ($3.5B).

• New Unicorns:

  • Eleven healthcare startups joined the unicorn club in Q2'21, with a total valuation of $27B.
  • There are currently 78 healthcare unicorns valued at $214B globally.

Sector Highlights

AI

• Funding reached a record high of $2.7B for the sixth consecutive quarter.
• Mega-rounds indicated broader applications of AI in healthcare, with notable companies like Exscientia and Recursion seeing high-profile exits.
• AI-based motion detection startups attracted significant mid-stage funding.

Digital Therapeutics

• Funding decreased slightly from Q1'21 but remained at $580M, well above prior levels.
• Established players raised capital to expand into new therapeutic areas, and hospital systems showed growing interest in digital therapeutics for unmet needs.

Telehealth

• Funding broke records for the fourth quarter in a row, reaching nearly $5B, a 165% YoY increase.
• The teletherapy, virtual health coaching, and care management segment represented nearly 40% of global telehealth deals.
• Major entrants like Walmart and Amazon continued to expand their telehealth offerings.

Omics

• Deals increased for the first time in 9 quarters, with funding jumping by 50% QoQ to a record high of $2.8B.
• Mega-rounds highlighted the expanding use cases of omics in healthcare, including genetic engineering.

Medical Devices

• Funding rebounded to $8.2B across 396 deals, a 70% QoQ increase.
• Late-stage mega-rounds included CMR Surgical’s $600M raise and Quanta’s $245M Series D.
• Early-stage deal share increased for the first time in 9 quarters.

Health IT

• Funding fell by over $600M, ending 6 consecutive quarters of growth.
• Late-stage deal share dropped to 9%, while mid-stage deal share increased to 47%.

Mental Health Tech

• Funding increased by over 50% QoQ to nearly $1.3B, driven by late-stage mega-rounds from DTx and teletherapy companies.
• The employee benefits space saw business development activity, and digital biomarker companies attracted VC backing.

Key Information

• Digital Transformation:
  • Continued to accelerate post-pandemic, with 60% of healthcare organizations adding new digital projects and 42% accelerating existing plans.
• Health Equity:
  • The pandemic highlighted social and health inequities, leading to increased focus on health equity.
• Tech Giants' Initiatives:
  • Facebook: Expanding into smartwatch and mental health resources.
  • Microsoft: Acquiring Nuance Communications and forming partnerships with health tech firms.
  • Google: Launching Derm Assist and investing in various health startups.
  • Amazon: Expanding Amazon Care and launching AWS Healthcare Accelerator.

Investment Trends

• Funding Growth:
  • Global healthcare funding continued to rise for the 7th quarter in a row.
• Regional Trends:
  • European investment nearly doubled QoQ, while Asian investment remained elevated despite a dip.
• Deal Stage:
  • Early-stage deal share reached 54%, signaling increased innovation and entry into the sector.

Summary of Findings

• Digital Health Dominance:
  • Digital health startups were the primary drivers of investment and deal activity.
• M&A and SPAC Activity:
  • M&A and SPAC exits were significant, with notable companies in AI, telehealth, and medical devices.
• Unicorn Growth:
  • The healthcare unicorn count reached 78 with a total valuation of $214B.
• Sector Innovation:
  • Medical innovation retained momentum, with a focus on AI, digital therapeutics, and omics technologies.
• Regulatory Reform:
  • Pressure for long-term telehealth regulatory reform increased, with lobbying efforts by major players.

Conclusion

Q2'21 marked a significant period of growth and transformation in the healthcare sector, with digital health leading the charge in terms of investment and innovation. Despite challenges in certain regions and sectors, the overall trend showed continued momentum in AI, telehealth, and medical devices, supported by substantial funding and strategic partnerships. The report underscores the evolving landscape of healthcare technology and its potential to reshape patient care and medical innovation.